11 GREAT VALLEY PARKWAY, MALVERN, PA
Investor Presentation
Provides Business Update with Second Quarter 2026 Financial Results
Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa
Material disclosure
Chief Accounting Officer Resignation; Rita Johnson-Greene Appointed
Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes
Ocugen, Inc. Completes $115 Million Private Offering of Convertible Notes
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
PRER14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Registration of Securities under Section 12(g)